, ,
(treatment-naive patient) ,
(treatment-experienced patient) .
. ABC, abacavir; ATV, atazanavir; d4T, stavudine; ddI, didanosine; DRV, darunavir; EFV, efavirenz; FTC, emtricitabine; HBV, hepatitis B virus; HCV, hepatitis C virus; IDV, indinavir; LPV, Lopinavir; MVC, maraviroc; NFV, nelfi navir; NVP, nevirapine; PI/r, protease inhibitors boosted with ritonavir; RAL, raltegravir; RPV, ripivirine; RTV, ritonavir; SQV, saquinavir; TDF, tenofovir; TPV, tipranavir; ZDV, zidovudine; 3TC, lamivudine.
(
[ [1] [2] [3] [4] . 
CD4+ T ,
HIV RNA (A-).
2.
(diff erential count) (complete blood count, CBC) (A-).
B (A-), C (A-), A (B-)
.
(A-) (B-
) .
5.
(tuberculin skin test, 
, (B-).
7.
(genotypic test) (A-).
50 (B-III).
, , ,
( Table 2) .
CD4+ T HIV RNA
, .
(2) CD4+ T
CD4+ T (A-).
CD4+ T , [5, 6] . , [7] [8] [9] . , 
(A-).
(B-).
30-40% , , 75% [10] . , (diff erential count) (complete blood count, CBC) (basic chemistry) (A ).
. [12](A-).
B (HBsAg, anti-HBs Ab) 
. , , , 
efavirenz (A-).
11. Abacavir HLA-B*5701
12.
(1 .
(B-).
19.
(A-).
(1)
HIV RNA HIV RNA 12-16 (B-).
2-3

24
(B-). 
24-48 , 48
( Table 3 ).
4 (A-).
(C-).
HIV RNA 1,000 copies/mL (A-). HIV RNA 500-1,000 copies/mL (B-).
HIV RNA 1,000 copies/mL (A-).
(1) (genotypic assay) (phenotypic assay) , (Table 4) . 500-2,000 copies/mL , 500-1,000 copies/mL .
10-20%
. , 4-6 4 [30-32](A-).
(C-). , (B-).
HIV RNA , . 
CD4+ T .
•
1) (A-)
2) (A-)
3) (HIV-associated ne-
HIV RNA
. ,
(2) (HIV-associated nephropathy) [51] . CD4+ T , , [52, 53] .
[ [54] [55] [56] . , (A-). 
efavirenz (A-), efavirenz rilpivirine
raltegravir NTRI backbone raltegravir (A-).
. (2) Pubmed ( TDF should be prescribed with caution in patients with renal diseases. 3 TDF and FTC co-formulated drug is available. 4 Fatal hypersensitivity reaction could be happen by ABC, retrial is contraindicated when hypersensitivity reaction is suspicious. 5 Hypersensitivity to ABC is related to HLA-B*5701. 6 Special caution is required when ABC is used in patients with (a) cardiovascular risk factor(s). 7 ABC and 3TC co-formulated drug is available. 8 Ritonavir-boosted PI. 9 Either LPV/r 400mg/100mg bid or 800mg/200mg qd is acceptable. 10 The frequency of side effects is higher than other PIs. 11 Special attention is required, when administered during 1 st trimester. 12 Should not be used in women with no effective and consistent contraception. 13 ZDV and 3TC coformulated drug is available. 14 Unboosted ATV should not be used with TDF. • (1) 3 (Table 5 column B) (genetic barrier to resistance)
, . [117].
Ritonavir-boosted atazanavir (A-)
Ritonavir-boosted atazanavir ,
[ 
efavirenz (A-), efavirenz rilpivirine (B-).
(1) 3 (Table 5 column B)
. nevirapine [131] (AI). (A-).
(A-).
4.
( < 50 copies/mL) (A-).
5.
, 3
(A-). , ,
[146](A-).
(A-).
( 1,000 copies/mL : .
.
2-4 (genotypic resistance test) (C-).
• 10,000-20,000 copies/mL [156, 157] .
(B-). CD4+ T 100 /uL (C-).
. [191, 192] . 19q13 rs12979860 C/C C/T T/T . IL-28B HCV HIV [193] . , IL-28B
, IL-28B HCV .
: ALT AST
. ALT AST , ALT [194] . , . HCV [57, 195, 196] . , [59] [60] [61] . , Abacavir peginterferon ribavirin . [199] [200] [201] . , HCV abacavir (B-).
[183].
• ( [202]. HCV [203] . ,
stavudine, nevirapine, (full-dose) ritonavir (600mg daily) [204] . , stavudine, didanosine, ziduvudine [205] , didanosine 
(A-). • . ,
X4 virus (overgrowth), 2) HIV gp120( , 
